These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11755367)

  • 1. First dual NK(1) antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants.
    Ryckmans T; Balançon L; Berton O; Genicot C; Lamberty Y; Lallemand B; Pasau P; Pirlot N; Quéré L; Talaga P
    Bioorg Med Chem Lett; 2002 Jan; 12(2):261-4. PubMed ID: 11755367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual NK(1) antagonists--serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives.
    Ryckmans T; Berton O; Grimée R; Kogej T; Lamberty Y; Pasau P; Talaga P; Genicot C
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3195-8. PubMed ID: 12372532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.
    Wu YJ; He H; Bertekap R; Westphal R; Lelas S; Newton A; Wallace T; Taber M; Davis C; Macor JE; Bronson J
    Bioorg Med Chem; 2013 Apr; 21(8):2217-2228. PubMed ID: 23477943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and Synthesis of Arylamidine Derivatives as Serotonin/Norepinephrine Dual Reuptake Inhibitors.
    Wen H; Qin W; Yang G; Guo Y
    Molecules; 2019 Jan; 24(3):. PubMed ID: 30704101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Indazoles as Potent, Orally Active Dual Neurokinin 1 Receptor Antagonists and Serotonin Transporter Inhibitors for the Treatment of Depression.
    Degnan AP; Tora GO; Huang H; Conlon DA; Davis CD; Hanumegowda UM; Hou X; Hsiao Y; Hu J; Krause R; Li YW; Newton AE; Pieschl RL; Raybon J; Rosner T; Sun JH; Taber MT; Taylor SJ; Wong MK; Zhang H; Lodge NJ; Bronson JJ; Macor JE; Gillman KW
    ACS Chem Neurosci; 2016 Dec; 7(12):1635-1640. PubMed ID: 27744678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
    Martínez-Esparza J; Oficialdegui AM; Pérez-Silanes S; Heras B; Orús L; Palop JA; Lasheras B; Roca J; Mourelle M; Bosch A; Del Castillo JC; Tordera R; Del Río J; Monge A
    J Med Chem; 2001 Feb; 44(3):418-28. PubMed ID: 11462981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT reuptake inhibitors with 5-HT(1B/1D) antagonistic activity: a new approach toward efficient antidepressants.
    Matzen L; van Amsterdam C; Rautenberg W; Greiner HE; Harting J; Seyfried CA; Böttcher H
    J Med Chem; 2000 Mar; 43(6):1149-57. PubMed ID: 10737747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances toward new antidepressants with dual serotonin transporter and 5-HT1A receptor affinity within a class of 3-aminochroman derivatives. Part 2.
    Hatzenbuhler NT; Baudy R; Evrard DA; Failli A; Harrison BL; Lenicek S; Mewshaw RE; Saab A; Shah U; Sze J; Zhang M; Zhou D; Chlenov M; Kagan M; Golembieski J; Hornby G; Lai M; Smith DL; Sullivan KM; Schechter LE; Andree TH
    J Med Chem; 2008 Nov; 51(21):6980-7004. PubMed ID: 18834188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Multimodal serotonergic antidepressants].
    Danilov DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9):103-111. PubMed ID: 29053130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of new 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives as potential antidepressants with a dual mode of action: serotonin reuptake inhibition and 5-HT1A receptor antagonism.
    Oficialdegui AM; Martinez J; Pérez S; Heras B; Irurzun M; Palop JA; Tordera R; Lasheras B; del Río J; Monge A
    Farmaco; 2000 May; 55(5):345-53. PubMed ID: 10983279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
    Andrews M; Brown A; Chiva JY; Fradet D; Gordon D; Lansdell M; MacKenny M
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5893-7. PubMed ID: 19740658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biaryls as potent, tunable dual neurokinin 1 receptor antagonists and serotonin transporter inhibitors.
    Degnan AP; Tora GO; Han Y; Rajamani R; Bertekap R; Krause R; Davis CD; Hu J; Morgan D; Taylor SJ; Krause K; Li YW; Mattson G; Cunningham MA; Taber MT; Lodge NJ; Bronson JJ; Gillman KW; Macor JE
    Bioorg Med Chem Lett; 2015 Aug; 25(15):3039-43. PubMed ID: 26048800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of novel compounds within a class of 3-aminochroman derivatives with dual 5-HT1A receptor and serotonin transporter affinity.
    Hatzenbuhler NT; Evrard DA; Harrison BL; Huryn D; Inghrim J; Kraml C; Mattes JF; Mewshaw RE; Zhou D; Hornby G; Lin Q; Smith DL; Sullivan KM; Schechter LE; Beyer CE; Andree TH
    J Med Chem; 2006 Jul; 49(15):4785-9. PubMed ID: 16854086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 5.
    Takeuchi K; Kohn TJ; Honigschmidt NA; Rocco VP; Spinazze PG; Hemrick-Luecke SK; Thompson LK; Evans DC; Rasmussen K; Koger D; Lodge D; Martin LJ; Shaw J; Threlkeld PG; Wong DT
    Bioorg Med Chem Lett; 2006 May; 16(9):2347-51. PubMed ID: 16298130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.
    Tamiya J; Dyck B; Zhang M; Phan K; Fleck BA; Aparicio A; Jovic F; Tran JA; Vickers T; Grey J; Foster AC; Chen C
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3328-32. PubMed ID: 18445525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and antidepressant-like activity of novel aralkyl piperazine derivatives targeting SSRI/5-HT
    Gu ZS; Zhou AN; Xiao Y; Zhang QW; Li JQ
    Eur J Med Chem; 2018 Jan; 144():701-715. PubMed ID: 29291438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Design, synthesis and pharmacological investigation of isoindoline derivatives as 5-HT/NE double reuptake inhibitors].
    Wen H; Shi Y; Dong JW; Guo YS; Zang JJ; Yang GZ
    Yao Xue Xue Bao; 2015 Sep; 50(9):1148-55. PubMed ID: 26757552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naphthyl piperazines with dual activity as 5-HT1D antagonists and 5-HT reuptake inhibitors.
    Bueno AB; Gilmore J; Boot J; Broadmore R; Cooper J; Findlay J; Hayhurst L; Marcos A; Montero C; Mitchell S; Timms G; Tomlinson R; Wallace L; Walton L
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3344-8. PubMed ID: 17434731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a cyclopentylamine as an orally active dual NK1 receptor antagonist-serotonin reuptake transporter inhibitor.
    Wu YJ; He H; Gao Q; Wu D; Bertekap R; Westphal RS; Lelas S; Newton A; Wallace T; Taber M; Davis C; Macor JE; Bronson J
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1611-4. PubMed ID: 24507922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies towards the next generation of antidepressants. Part 4: derivatives of 4-(5-fluoro-1H-indol-3-yl)cyclohexylamine with affinity for the serotonin transporter and the 5-HT1A receptor.
    Evrard DA; Zhou P; Yi SY; Zhou D; Smith DL; Sullivan KM; Hornby GA; Schechter LE; Andree TH; Mewshaw RE
    Bioorg Med Chem Lett; 2005 Feb; 15(4):911-4. PubMed ID: 15686885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.